As we research and develop new drugs, we will always consider how to get them to more people as quickly as possible, regardless of where they live. We will systematically assess our R&D portfolio against the unmet needs of underserved populations and integrate these needs, as appropriate, into our drug discovery and development strategy.
Our innovation process will include adapting existing products for different types of patients or diseases and for diverse environments
We will aim to make our products available in countries with the highest burden of the disease to be treated
We will continue our work to reduce the burden of infectious and tropical diseases